PMID- 28257394
OWN - NLM
STAT- MEDLINE
DCOM- 20180424
LR  - 20180711
IS  - 1473-5636 (Electronic)
IS  - 0960-8931 (Linking)
VI  - 27
IP  - 4
DP  - 2017 Aug
TI  - Reinduction of PD1-inhibitor therapy: first experience in eight patients with
      metastatic melanoma.
PG  - 321-325
LID - 10.1097/CMR.0000000000000341 [doi]
AB  - Significant progress has been made in the treatment of metastatic melanoma during
      the last years. Approval of immune-checkpoint inhibitors and targeted therapies
      has been achieved recently. The sequencing of these therapies is an important
      issue. Here, we report our experience with the treatment and retreatment with
      PD1-inhibitors (PD1i) in eight patients. The patients (two female and seven male 
      with a median age of 70 years, all melanoma stage IV, M1c) underwent a first
      treatment period with PD1i for a median of 5.5 months. Three (37.5%) patients had
      a stable disease as best response, two (25%) showed progression, two (25%) showed
      partial response, and one (12.5%) achieved complete remission. PD1i was
      discontinued due to disease progression in seven patients and due to side effects
      (pancreatitis) in one patient. Patients were subsequently treated with ipilimumab
      (n=2), or chemotherapy (n=4), or no other medical treatment (n=2). All eight
      patients were subsequently retreated with PD1i for a median of 2.5 months. One
      (12.5%) developed a partial response, whereas in three patients (37.5%) the
      disease was stabilized. PD1i have shown a high and durable response rate in the
      first-line treatment of metastatic melanoma. Our study suggests PD1i retreatment 
      as a reasonable option for selected patients. Further investigations are needed
      to verify the value of PD1i re-exposure and to identify subgroups of patients who
      can benefit.
FAU - Blasig, Hanna
AU  - Blasig H
AD  - aDepartment of Dermatology and Allergy Hannover Medical School, Skin Cancer
      Center Hannover, Hannover bDepartment of Dermatology, University Hospital
      Heidelberg, Heidelberg cDepartment of Dermatology, University Hospital Tuebingen,
      Tuebingen dDepartment of Dermatology, Phlebology and Allergology, Hospital
      Bremerhaven-Reinkenheide, Bremerhaven, Germany.
FAU - Bender, Carolin
AU  - Bender C
FAU - Hassel, Jessica C
AU  - Hassel JC
FAU - Eigentler, Thomas K
AU  - Eigentler TK
FAU - Sachse, Michael M
AU  - Sachse MM
FAU - Hiernickel, Julia
AU  - Hiernickel J
FAU - Koop, Anika
AU  - Koop A
FAU - Satzger, Imke
AU  - Satzger I
FAU - Gutzmer, Ralf
AU  - Gutzmer R
LA  - eng
PT  - Journal Article
PL  - England
TA  - Melanoma Res
JT  - Melanoma research
JID - 9109623
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Aged
MH  - Female
MH  - Humans
MH  - Male
MH  - Melanoma/pathology/*therapy
MH  - Middle Aged
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors
MH  - Retrospective Studies
MH  - Skin Neoplasms/pathology/*therapy
EDAT- 2017/03/04 06:00
MHDA- 2018/04/25 06:00
CRDT- 2017/03/04 06:00
PHST- 2017/03/04 06:00 [pubmed]
PHST- 2018/04/25 06:00 [medline]
PHST- 2017/03/04 06:00 [entrez]
AID - 10.1097/CMR.0000000000000341 [doi]
PST - ppublish
SO  - Melanoma Res. 2017 Aug;27(4):321-325. doi: 10.1097/CMR.0000000000000341.